CLLS

Cellectis S.A. is a clinical-stage biopharmaceutical company developing immunotherapies based on gene-edited allogeneic CAR T-cells. Headquartered in Paris, France, the company uses its proprietary TALEN gene-editing technology to create off-the-shelf CAR T-cell products targeting hematological malignancies and solid tumors. Cellectis' lead programs include UCART19 and UCART22 for B-cell cancers, designed to provide readily available alternatives to patient-specific CAR T therapies. The company also licenses its gene-editing platform to partners in agriculture and other industries.